Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomised, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)

NCT04330326 is registered in ClinicalTrials.gov with ScandiBio Therapeutics AB as lead sponsor.

NCT NCT04330326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04330326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomised, Placebo Controlled Study to Evaluate the Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation in Obese Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Lead sponsor
ScandiBio Therapeutics AB
Phase
Phase 2
Overall status
Completed
Start date
July 20, 2019
Completion date
May 6, 2022
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic fatty liver disease (nafld)